Sustaining cardiac claudin-5 levels prevents functional hallmarks of cardiomyopathy in a muscular dystrophy mouse model

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1378-1383

  Delfín, Dawn A ^a   Xu, Ying ^a   Schill, Kevin E ^a   Mays, Tessily A ^a   Canan, Benjamin D ^a   Zang, Kara E ^a   Barnum, Jamie A ^a   Janssen, Paul M L ^a   Rafael Fortney, Jill A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 5; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARDIOMYOPATHY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EXPERIMENTAL MOUSE; HEART FAILURE; HISTOPATHOLOGY; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PROTEIN FUNCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENO-ASSOCIATED VIRUS;

EID: 84863442061     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.81     Document Type: Article

References (29)

1. Kaspar, RW, Allen, HD and Montanaro, F (2009). Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. J Am Acad Nurse Pract 21: 241-249.
2. Hermans, MC, Pinto, YM, Merkies, IS, de Die-Smulders, CE, Crijns, HJ and Faber, CG (2010). Hereditary muscular dystrophies and the heart. Neuromuscul Disord 20: 479-492.
3. Duan, D (2006). Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet 15 Spec No 2: R253-R261. (Pubitemid 44446801)
4. Townsend, D, Yasuda, S, Li, S, Chamberlain, JS and Metzger, JM (2008). Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 16: 832-835. (Pubitemid 351587091)
5. Rafael, JA, Tinsley, JM, Potter, AC, Deconinck, AE and Davies, KE (1998). Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet 19: 79-82. (Pubitemid 28242029)
6. Deconinck, AE, Rafael, JA, Skinner, JA, Brown, SC, Potter, AC, Metzinger, L et al. (1997). Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717-727. (Pubitemid 27357963)
7. Hainsey, TA, Senapati, S, Kuhn, DE and Rafael, JA (2003). Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovasculature. Neuromuscul Disord 13: 294-302. (Pubitemid 36966160)
8. Janssen, PM, Hiranandani, N, Mays, TA and Rafael-Fortney, JA (2005). Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 289: H2373-H2378. (Pubitemid 41698545)
9. Sanford, JL, Edwards, JD, Mays, TA, Gong, B, Merriam, AP and Rafael-Fortney, JA (2005). Claudin-5 localizes to the lateral membranes of cardiomyocytes and is altered in utrophin/dystrophin-deficient cardiomyopathic mice. J Mol Cell Cardiol 38: 323-332. (Pubitemid 40215202)
10. Baker, PE, Kearney, JA, Gong, B, Merriam, AP, Kuhn, DE, Porter, JD et al. (2006). Analysis of gene expression differences between utrophin/dystrophin- deficient vs mdx skeletal muscles reveals a specific upregulation of slow muscle genes in limb muscles. Neurogenetics 7: 81-91.
11. Mays, TA, Binkley, PF, Lesinski, A, Doshi, AA, Quaile, MP, Margulies, KB et al. (2008). Claudin-5 levels are reduced in human end-stage cardiomyopathy. J Mol Cell Cardiol 45: 81-87.
12. Dupont, E, Matsushita, T, Kaba, RA, Vozzi, C, Coppen, SR, Khan, N et al. (2001). Altered connexin expression in human congestive heart failure. J Mol Cell Cardiol 33: 359-371. (Pubitemid 32537933)
13. Müller, AL and Dhalla, NS (2012). Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 17: 395-409.
14. Vatta, M, Stetson, SJ, Perez-Verdia, A, Entman, ML, Noon, GP, Torre-Amione, G et al. (2002). Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 359: 936-941. (Pubitemid 34246384)
15. Gregorevic, P, Allen, JM, Minami, E, Blankinship, MJ, Haraguchi, M, Meuse, L et al. (2006). rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12: 787-789. (Pubitemid 44050067)
16. Gregorevic, P, Blankinship, MJ, Allen, JM, Crawford, RW, Meuse, L, Miller, DG et al. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10: 828-834. (Pubitemid 39070856)
17. Townsend, D, Blankinship, MJ, Allen, JM, Gregorevic, P, Chamberlain, JS and Metzger, JM (2007). Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 15: 1086-1092. (Pubitemid 46813611)
18. Bristow, MR, Ginsburg, R, Minobe, W, Cubicciotti, RS, Sageman, WS, Lurie, K et al. (1982). Decreased catecholamine sensitivity and beta-adrenergic- receptor density in failing human hearts. N Engl J Med 307: 205-211. (Pubitemid 12079105)
19. Au, CG, Butler, TL, Sherwood, MC, Egan, JR, North, KN and Winlaw, DS (2011). Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int J Exp Pathol 92: 57-65.
20. Janssen, PM (2010). Kinetics of cardiac muscle contraction and relaxation are linked and determined by properties of the cardiac sarcomere. Am J Physiol Heart Circ Physiol 299: H1092-H1099.
21. Stull, LB, Leppo, MK, Marbán, E and Janssen, PM (2002). Physiological determinants of contractile force generation and calcium handling in mouse myocardium. J Mol Cell Cardiol 34: 1367-1376. (Pubitemid 35244414)
22. Straub, V, Rafael, JA, Chamberlain, JS and Campbell, KP (1997). Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol 139: 375-385. (Pubitemid 27459311)
23. Kabaeva, Z, Meekhof, KE and Michele, DE (2011). Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor function. Hum Mol Genet 20: 3346-3355.
24. Michele, DE, Kabaeva, Z, Davis, SL, Weiss, RM and Campbell, KP (2009). Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage. Circ Res 105: 984-993.
25. Morita, K, Sasaki, H, Furuse, M and Tsukita, S (1999). Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 147: 185-194. (Pubitemid 30211806)
26. Fedak, PW, Verma, S, Weisel, RD and Li, RK (2005). Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol 14: 1-11. (Pubitemid 40248426)
27. Puchalski, MD, Williams, RV, Askovich, B, Sower, CT, Hor, KH, Su, JT et al. (2009). Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? Int J Cardiovasc Imaging 25: 57-63.
28. Verhaert, D, Richards, K, Rafael-Fortney, JA and Raman, SV (2011). Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging 4: 67-76.
29. Bostick, B, Yue, Y, Long, C and Duan, D (2008). Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 102: 121-130.